Lundbeck to acquire Abide Therapeutics for $250 million
Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.
In a statement on Monday, May 6, Lundbeck said it had signed a definitive agreement under which it will pay $250 million upfront to acquire the biotechnology company.
It said it will also pay future development and sales milestones to the current owners of up to $150 million.
Lundbeck said the acquisition provides it with a novel discovery platform and a US-based research hub.
Deborah Dunsire, the president and CEO of Lundbeck said: “Abide’s innovative research and development platform will provide it with a unique opportunity to strengthen its pipeline.”
Abide’s platform has previously discovered potent and selective serine hydrolase inhibitors, one of the largest classes of enzymes found in nature.
Serine hydrolases have vital roles in many pathophysiological processes, including blood clotting, digestion, nervous system signalling, inflammation and cancer.
After closing, Abide’s laboratory in La Jolla, California, will become a US-based drug discovery hub for Lundbeck.
“Lundbeck’s commitment to brain health convinced us that this was the best way to attain Abide’s goal to develop novel therapeutics that make a fundamental difference in the lives of patients,” said Alan Ezekowitz, CEO of Abide.
The transaction is expected to close during the second quarter of 2019.
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk